Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-119741 · Präparat HOS-095005
12
OESTROGEN-BASED CONTRACEPTIVES
Ethinylestradiol ethinylestradiol The combination of
0.035 mg once daily AUC ↑ 1.22 (1.13-1.31) oestrogen- and/or
Norethindrone Cmin ↔ 1.09 (1.01-1.18) progesterone-based
1 mg once daily Cmax ↑ 1.33 (1.21-1.46) contraceptives and
norethindrone INTELENCE can be used
AUC ↔ 0.95 (0.90-0.99) without dose adjustment.
Cmin ↓ 0.78 (0.68-0.90)
Cmax ↔ 1.05 (0.98-1.12)
etravirine
AUC ↔a
Cmin ↔a
Cmax ↔a
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
Ribavirin Not studied, but no interaction expected based The combination of
on the renal elimination pathway of ribavirin. INTELENCE and ribavirin
can be used without dose
adjustments.
Daclatasvir Not studied. Co-administration of etravirine Co-administration of
with daclatasvir may decrease daclatasvir INTELENCE and daclatasvir
concentrations. is not recommended.
Elbasvir/grazoprevir Not studied. Co-administration of etravirine Co-administration is
with elbasvir/grazoprevir may decrease elbasvir contraindicated (see
and grazoprevir concentrations, leading to section 4.3).
reduced therapeutic effect of
elbasvir/grazoprevir.
HERBAL PRODUCTS
St John’s wort Not studied. St John’s wort is expected to Combination not
(Hypericum perforatum)
decrease the plasma concentrations of recommended.
etravirine.
HMG CO-A REDUCTASE INHIBITORS
Atorvastatin atorvastatin The combination of
40 mg once daily AUC ↓ 0.63 (0.58-0.68) INTELENCE and
Cmin ND atorvastatin can be given
Cmax ↑ 1.04 (0.84-1.30) without any dose
2-OH-atorvastatin adjustments, however, the
AUC ↑ 1.27 (1.19-1.36) dose of atorvastatin may
Cmin ND need to be altered based on
Cmax ↑ 1.76 (1.60-1.94) clinical response.
etravirine
AUC ↔ 1.02 (0.97-1.07)
Cmin ↔ 1.10 (1.02-1.19)
Cmax ↔ 0.97 (0.93-1.02)
Fluvastatin Not studied. No interaction between pravastatin Dose adjustments for these
Lovastatin and etravirine is expected. HMG Co-A reductase
Pravastatin Lovastatin, rosuvastatin and simvastatin are inhibitors may be necessary.
Rosuvastatin CYP3A4 substrates and co-administration with
Simvastatin etravirine may result in lower plasma
concentrations of the HMG Co-A reductase
inhibitor. Fluvastatin, and rosuvastatin are
metabolised by CYP2C9 and co-administration
with etravirine may result in higher plasma
concentrations of the HMG Co-A reductase
inhibitor.
H2-RECEPTOR ANTAGONISTS
Ranitidine etravirine INTELENCE can be
150 mg twice daily AUC ↓ 0.86 (0.76-0.97) co-administered with
Cmin ND H2-receptor antagonists
Cmax ↓ 0.94 (0.75-1.17) without dose adjustments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) daclatasvir (HOS-119742) lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) hepatitis C virus (HOS-108813) ribavirin (HOS-088127) grazoprevir (HOS-108815) ranitidine (HOS-085660) norethindrone (HOS-088136) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage b4ae62f3b56de12cf8406dcb55d38bc3538cd806a08b537965c6bb7ead0cc339 · Zeichen 24913–29265 im Abschnitt
Wechselwirkungen · Tivicay
Tivicay 10 mg film-coated tablets Tivicay 25 mg film-coated tablets Tivicay 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-129163 · Präparat HOS-096689
8
Darunavir/ritonavir Dolutegravir No dose adjustment is necessary.
AUC 22%
Cmax 11%
C24 38%
(induction of UGT1A1 and
CYP3A enzymes)
Lopinavir/ritonavir Dolutegravir No dose adjustment is necessary.
AUC 4%
Cmax 0%
C24 6%
Other Antiviral agents
Daclatasvir Dolutegravir Daclatasvir did not change dolutegravir plasma
AUC 33% concentration to a clinically relevant extent.
Cmax 29% Dolutegravir did not change daclatasvir plasma
C 45% concentration. No dose adjustment is necessary.
Daclatasvir
Other agents
Potassium channel blocker
Fampridine (also Fampridine Co-administration of dolutegravir has the potential
known as to cause seizures due to increased fampridine
dalfampridine) plasma concentration via inhibition of OCT2
transporter; co-administration has not been studied.
Fampridine co-administration with dolutegravir is
contraindicated.
Anticonvulsants
Carbamazepine Dolutegravir The recommended adult dose of dolutegravir is 50
AUC 49% mg twice daily when co-administered with
Cmax 33% carbamazepine. In paediatric patients the weight-
C 73% based once daily dose should be administered
twice daily. Alternatives to carbamazepine should
be used where possible for INI resistant patients.
Oxcarbazepine Dolutegravir The recommended adult dose of dolutegravir is 50
Phenytoin (Not studied, decrease mg twice daily when co-administered with these
Phenobarbital expected due to induction of metabolic inducers. In paediatric patients the
UGT1A1 and CYP3A weight-based once daily dose should be
enzymes, a similar reduction administered twice daily. Alternative
in exposure as observed combinations that do not include these metabolic
with carbamazepine is inducers should be used where possible in INI-
expected) resistant patients.
Azole anti-fungal agents
Ketoconazole Dolutegravir No dose adjustment is necessary. Based on data
Fluconazole (Not studied) from other CYP3A4 inhibitors, a marked increase
Itraconazole is not expected.
Posaconazole
Voriconazole
Herbal products
St. John’s wort Dolutegravir The recommended adult dose of dolutegravir is 50
(Not studied, decrease mg twice daily when co-administered with St.
expected due to induction of John’s wort. In paediatric patients the weight-
UGT1A1 and CYP3A based once daily dose should be administered
enzymes, a similar reduction twice daily. Alternative combinations that do not
in exposure as observed include St. John’s wort should be used where
with carbamazepine is possible in INI-resistant patients.
expected)
Antacids and supplements
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) daclatasvir (HOS-119742) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) voriconazole (HOS-084524) itraconazole (HOS-084516) dalfampridine (HOS-124191) fluconazole (HOS-087945) darunavir (HOS-086181) oxcarbazepine (HOS-110224) ritonavir (HOS-084521) potassium (HOS-086929) phenytoin (HOS-084531) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:54:00Z · SHA-256 49ffb99144edc826feca26a0b941946b69a295b5c67e5f5fd79358277916c087 · Passage 7146ae3c08ab0159cbd699143845d13f9721ca0ad65d42e769709558e2d4148f · Zeichen 9118–13250 im Abschnitt
Wechselwirkungen · Tivicay
Tivicay 5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 38–39
HOS-129200 · Präparat HOS-096689
38
Lopinavir/ritonavir Dolutegravir No dose adjustment is necessary.
AUC 4%
Cmax 0%
C24 6%
Other Antiviral agents
Daclatasvir Dolutegravir Daclatasvir did not change dolutegravir plasma
AUC 33% concentration to a clinically relevant extent.
Cmax 29% Dolutegravir did not change daclatasvir plasma
C 45% concentration. No dose adjustment is necessary.
Daclatasvir
Other agents
Potassium channel blocker
Fampridine (also Fampridine Co-administration of dolutegravir has the potential
known as to cause seizures due to increased fampridine
dalfampridine) plasma concentration via inhibition of OCT2
transporter; co-administration has not been studied.
Fampridine co-administration with dolutegravir is
contraindicated.
Anticonvulsants
Carbamazepine Dolutegravir The recommended adult dose of dolutegravir
AUC 49% should be given twice daily when co-administered
Cmax 33% with carbamazepine. In paediatric patients the
C 73% weight-based once daily dose should be
administered twice daily. Alternatives to
carbamazepine should be used where possible for
INI resistant patients.
Oxcarbazepine Dolutegravir The recommended adult dose of dolutegravir
Phenytoin (Not studied, decrease should be given twice daily when co-administered
Phenobarbital expected due to induction of with these metabolic inducers. In paediatric
UGT1A1 and CYP3A patients the weight-based once daily dose should
enzymes, a similar reduction be administered twice daily. Alternative
in exposure as observed combinations that do not include these metabolic
with carbamazepine is inducers should be used where possible in INI-
expected) resistant patients.
Azole anti-fungal agents
Ketoconazole Dolutegravir No dose adjustment is necessary. Based on data
Fluconazole (Not studied) from other CYP3A4 inhibitors, a marked increase
Itraconazole is not expected.
Posaconazole
Voriconazole
Herbal products
St. John’s wort Dolutegravir The recommended adult dose of dolutegravir
(Not studied, decrease should be given twice daily when co-administered
expected due to induction of with St. John’s wort. In paediatric patients the
UGT1A1 and CYP3A weight-based once daily dose should be
enzymes, a similar reduction administered twice daily. Alternative combinations
in exposure as observed that do not include St. John’s wort should be used
with carbamazepine is where possible in INI-resistant patients.
expected)
Antacids and supplements
Magnesium/ Dolutegravir Magnesium/ aluminium-containing antacid should
aluminium-containing AUC 74% be taken well separated in time from the
antacid Cmax 72% administration of dolutegravir (minimum 2 hours
(Complex binding to after or 6 hours before).
polyvalent ions)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) daclatasvir (HOS-119742) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) voriconazole (HOS-084524) itraconazole (HOS-084516) dalfampridine (HOS-124191) fluconazole (HOS-087945) oxcarbazepine (HOS-110224) ritonavir (HOS-084521) potassium (HOS-086929) magnesium (HOS-085165) phenytoin (HOS-084531) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:54:00Z · SHA-256 49ffb99144edc826feca26a0b941946b69a295b5c67e5f5fd79358277916c087 · Passage b1f6422443cc14d5f9a656df820bb5371607b232b50be9270e4f54627fc6d01d · Zeichen 9496–13843 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-129259 · Präparat HOS-096703
Darunavir ↔
Ritonavir ↔
(induction of UGT1A1
and CYP3A enzymes)
Other antiviral agents
Daclatasvir/Dolutegravir Dolutegravir ↔ Daclatasvir did not change dolutegravir
AUC ↑ 33% plasma concentration to a clinically
Cmax ↑ 29% relevant extent. Dolutegravir did not
Cτ ↑ 45% change daclatasvir plasma concentration.
Daclatasvir ↔ No dose adjustment is necessary.
Anti-infective products
Trimethoprim/sulfamethoxazole Interaction not studied No Triumeq dose adjustment necessary,
(Co-trimoxazole)/Abacavir unless patient has renal impairment (See
Section 4.2).
Trimethoprim/sulfamethoxazole Lamivudine:
(Co-trimoxazole)/Lamivudine AUC ↑43%
(160mg/800mg once daily for 5 Cmax ↑7%
days/300mg single dose)
Trimethoprim:
AUC ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) daclatasvir (HOS-119742) trimethoprim (HOS-085184) darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 20bcdf7a5d130859dc3724699b6dc292d6e8efc98705cfbe46385aa35a1e2d27 · Zeichen 14788–16009 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 48
HOS-129354 · Präparat HOS-096703
Darunavir ↔
Ritonavir ↔
(induction of UGT1A1
and CYP3A enzymes)
Other antiviral agents
Daclatasvir/Dolutegravir Dolutegravir ↔ Daclatasvir did not change dolutegravir
AUC ↑ 33% plasma concentration to a clinically
Cmax ↑ 29% relevant extent. Dolutegravir did not
Cτ ↑ 45% change daclatasvir plasma concentration.
Daclatasvir ↔ No dose adjustment is necessary.
Anti-infective products
Trimethoprim/sulfamethoxazole Interaction not studied No Triumeq dose adjustment necessary,
(Co-trimoxazole)/Abacavir unless patient has renal impairment (See
Section 4.2).
Trimethoprim/sulfamethoxazole Lamivudine:
(Co-trimoxazole)/Lamivudine AUC ↑43%
(160mg/800mg once daily for 5 Cmax ↑7%
days/300mg single dose)
Trimethoprim:
AUC ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) daclatasvir (HOS-119742) trimethoprim (HOS-085184) darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 20bcdf7a5d130859dc3724699b6dc292d6e8efc98705cfbe46385aa35a1e2d27 · Zeichen 12686–13907 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-138493 · Präparat HOS-098200
14
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Based on theoretical considerations Co-administration of Symtuza
bosentan is expected to decrease and bosentan is not
darunavir and/or cobicistat plasma recommended.
concentrations.
(CYP3A induction)
Symtuza is expected to increase
bosentan plasma concentrations.
(CYP3A inhibition)
ERGOT DERIVATIVES
e.g. Based on theoretical considerations Co-administration of Symtuza
Dihydroergotamine DRV/COBI may increase ergot and ergot derivatives is
Ergometrine derivative exposure. contraindicated (see section 4.3).
Ergotamine
Methylergonovine
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A inhibitors
Elbasvir/grazoprevir Based on theoretical considerations Concomitant use of Symtuza with
Symtuza may increase the elbasvir/grazoprevir is
exposure to grazoprevir. contraindicated (see section 4.3).
(OATP1B and CYP3A inhibition)
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
DRV/COBI may increase the co-administer Symtuza with
exposure to glecaprevir and glecaprevir/pibrentasvir.
pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
Daclatasvir Based on theoretical Symtuza and sofosbuvir,
Ledipasvir considerations, no clinically sofosbuvir/ledipasvir, or
Sofosbuvir relevant interaction is expected. daclatasvir can be used
concomitantly without dose
adjustment
Herbal products
St. John’s Wort (Hypericum
Based on theoretical consideration, The concomitant use of Symtuza
perforatum) St. John’s Wort may substantially with these medicinal products is
decrease DRV/COBI (CYP3A4 contraindicated (see section 4.3).
induction) and TAF exposures.
(P-gp induction)
HMG CO-A REDUCTASE INHIBITORS
Atorvastatin Atorvastatin (10 mg once daily): Concomitant use of a HMG CoA
Fluvastatin atorvastatin AUC ↑ 290% reductase inhibitor and Symtuza
Pitavastatin atorvastatin Cmax ↑ 319% may increase plasma
Pravastatin atorvastatin Cmin ND concentrations of the lipid
Rosuvastatin lowering agent, which may lead
Rosuvastatin (10 mg once daily): to adverse reactions such as
rosuvastatin AUC ↑ 93% myopathy.
rosuvastatin Cmax ↑ 277% When administration of
rosuvastatin Cmin ND HMG CoA reductase inhibitors
and Symtuza is desired, it is
Based on theoretical considerations recommended to start with the
DRV/COBI is expected to increase lowest dose and titrate up to the
the plasma concentrations of desired clinical effect while
fluvastatin, pitavastatin, monitoring for safety.
pravastatin, lovastatin and
Lovastatin simvastatin. Concomitant use of Symtuza with
Simvastatin (CYP3A inhibition and/or lovastatin and simvastatin is
transport) contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) methylergonovine (HOS-086155) daclatasvir (HOS-119742) sofosbuvir (HOS-108928) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) ledipasvir (HOS-110493) simvastatin (HOS-086158) rosuvastatin (HOS-086307) glecaprevir (HOS-086297) fluvastatin (HOS-086305) hepatitis C virus (HOS-108813) lead (HOS-085592) grazoprevir (HOS-108815) ergotamine (HOS-086154) bosentan (HOS-086291) dihydroergotamine (HOS-086152) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 7dedc11142e46d7502bc7e251f11ffb3c178eac67ce8ce16fb9ccc902e5f3904 · Zeichen 28527–32949 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-138671 · Präparat HOS-098240
Entecavir/ Rilpivirine Rilpivirine
(Not studied)
Daclatasvir/ Dolutegravir No dose adjustment is required.
Dolutegravir1 AUC 33%
Cmax 29%
C 45%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daclatasvir (HOS-119742) entecavir (HOS-088124)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 7a74be383ddfce73105fe02b1c0f3db23c970d527498db4ed08adf773746e6e5 · Zeichen 6040–6306 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-138672 · Präparat HOS-098240
Daclatasvir
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daclatasvir (HOS-119742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 6c519f1b4f9c07e3552a7f8dfb02c8214196e2d0392f8c5e9d1543714fae6ed4 · Zeichen 6333–6346 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-138673 · Präparat HOS-098240
Daclatasvir/ Rilpivirine
Rilpivirine
Simeprevir/ Dolutegravir No dose adjustment is required.
Dolutegravir
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daclatasvir (HOS-119742) simeprevir (HOS-086302)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 65c050f1827ae903e3c393a7edc6d5b3e293d7637190b5a252bc6aa36f0d031c · Zeichen 6348–6489 im Abschnitt
Wechselwirkungen · Delstrigo
Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-141200 · Präparat HOS-098610
Expected:
doravirine
Interaction not studied with
doravirine or
doravirine/lamivudine/tenofovir
daclatasvir
disoproxil. No dose adjustment is required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) daclatasvir (HOS-119742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage 136cb66c0d7afe11996e52e38634a846e03e743fb42f8de88c8649321460cfd6 · Zeichen 21995–22325 im Abschnitt
Wechselwirkungen · Pifeltro
Pifeltro 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-141264 · Präparat HOS-098618
GS-331007
AUC 1.03 (0.98, 1.09)
Cmax 1.03 (0.97, 1.09)
Interaction not studied.
sofosbuvir/velpatasvir No dose adjustment is required.
Expected:
doravirine
Interaction not studied.
sofosbuvir No dose adjustment is required.
Expected:
doravirine
Interaction not studied.
daclatasvir
No dose adjustment is required.
Expected:
↔ doravirine
Interaction not studied.
ombitasvir/
Expected:
paritaprevir/ritonavir and No dose adjustment is required.
doravirine
dasabuvir+/-ritonavir
(Inhibition of CYP3A due to
ritonavir)
Interaction not studied.
dasabuvir Expected: No dose adjustment is required.
doravirine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daclatasvir (HOS-119742) sofosbuvir (HOS-108928) dasabuvir (HOS-110302) ombitasvir (HOS-110300) velpatasvir (HOS-108929) ritonavir (HOS-084521) paritaprevir (HOS-110301)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T08:41:00Z · SHA-256 e669d0797aaecb09c38b8d2518d46b353834062d76517638eed9a33ed2fd94be · Passage 7a6aff4b5ae442d9eab5762e15c9e3ab5f8d6fd0a2549b2c092f26202ede10fe · Zeichen 14152–15538 im Abschnitt
Wechselwirkungen · Dovato
Dovato 50 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-142831 · Präparat HOS-098886
Darunavir
Ritonavir
(induction of UGT1A1
and CYP3A enzymes)
Other antiviral active substances
Daclatasvir/Dolutegravir Dolutegravir Daclatasvir did not change dolutegravir
AUC 33% plasma concentration to a clinically
Cmax 29% relevant extent. Dolutegravir did not
C 45% change daclatasvir plasma concentration.
Daclatasvir No dose adjustment is necessary.
Ledipasvir/Sofosbuvir/ Lamivudine No dosage adjustment necessary.
Lamivudine (with abacavir) Ledipasvir
Sofosbuvir
Sofosbuvir/ Dolutegravir No dosage adjustment necessary.
Velpatasvir/Dolutegravir Sofosbuvir
Velpatasvir
Ribavirin Interaction not studied. No dosage adjustment necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daclatasvir (HOS-119742) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) ribavirin (HOS-088127) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) abacavir (HOS-088077)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T01:22:00Z · SHA-256 9ebb38c4be2b7abc7ba2934afb44e75aa1d6b86e46ecc069e568b333119de792 · Passage b6f62f3d686305b8b1b2e5d70d8a7f365fd64114fce4b1f366c62d2c147e757f · Zeichen 13673–14818 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.